

3Q 2026 Earnings Presentation

October 28, 2026



GE HealthCare

Forward-looking statements and additional information

This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about our business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and our outlook and medium-term financial targets; changes in our leadership and related impacts; the impacts of macroeconomic and market conditions, including the impact of tariffs and other trade restrictions, and volatility on our business, operations, financial results, and financial position and on supply chains and the world economy; our cost structure; the impacts on our business of manufacturing, sourcing, and supply chain management; foreign currency exchange rates; operational performance; demand in the global markets in which we operate; and our strategy, innovation, and acquisitions and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Factors that could cause our actual results to differ materially from those described in our forward-looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflicts and tensions, including between Ukraine and Russia, in the Middle East, and in other regions; public health crises, epidemics, and pandemics, and their effects on our business; changes in or elimination of government subsidies, and changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for our products, services, or solutions and factors that affect that demand; developments in the market in China; our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions; our ability to successfully complete strategic transactions; the actions or inactions of third parties with whom we partner and the various collaboration, licensing, and other partnerships and alliances we have with third parties; the impacts related to our increasing focus on and investment in cloud, edge computing, artificial intelligence, and software offerings; management of our supply chain and our ability to cost-effectively secure the materials we need to operate our business; disruptions in our operations; the impact of potential information technology, cybersecurity, or data security breaches; maintenance and protection of our intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; our ability to attract and/or retain key talent and qualified employees; increasing attention to sustainability matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which we are subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability claims or potential litigation, arbitration, or similar proceedings; and our level of indebtedness and the impact of complying with the covenants and other terms of our debt instruments on our business. Please also see Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission and any updates or amendments we make in future filings. There may be other factors not presently known to us or which we currently consider to be immaterial that could cause our actual results to differ materially from those projected in any forward-looking statements we make. We do not undertake any obligation to update or revise our forward-looking statements except as required by applicable law or regulation.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures. See appendix for definitions, reconciliations of historical GAAP to non-GAAP financial measures, and for more information on our Outlook.

Financial Rounding

Certain columns and rows throughout this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

Product Status

Not all products or features are available in all markets. The information presented here may involve technologies and concepts in development that are not products and may never become products. For Technology in Development, the technologies or concepts are not being offered for sale, and are not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

3Q 2026 Update

- Delivered strong revenue growth and margin expansion across all segments; robust EPS growth
- Healthy orders, book-to-bill and backlog reflect continued customer investment and demand for new products
- Heartbeat improving commercial execution, visibility and productivity
- Strong execution in Patient Care Solutions recovery; strategic review ongoing
- Raising full year 2026 guidance; reflects improved performance year-to-date and momentum in the business

Note: Not all products available in all regions.



Expanded ultrasound platforms across cardiovascular, women's health, general imaging and handheld; supporting increased demand for minimally invasive diagnostics

Advancing our growth strategy enabled by Heartbeat

Precision care



D3: Smart devices and drugs, across disease states, enabled by digital, AI and software solutions

- **Achieved key regulatory milestones** for Photonova™ Spectra photon-counting CT and StarGuide™ GX next generation SPECT/CT
- **Expanded ultrasound platform** with new systems and enhanced AI features across care areas
- **Strong growth in contrast media and PET radiopharmaceutical**, including Vizamyl™, Cerianna™ and Flyrcado™

Growth acceleration



Positioned to accelerate top-line growth with innovation over the medium-term

- Revenue growth driven by **strong commercial execution and customer adoption of NPIs** in AIS and PDx
- **Services growth** driven by strong product attachment rates and contributions from Intelrad
- Announced planned acquisition of **SOFIE Biosciences**⁽¹⁾ for final mile of U.S. radiopharmaceutical supply and pipeline opportunity

Business optimization



Focus on enhancing customer satisfaction and margin expansion

- Strategic **price and cost actions** positively impacting results
- **Strengthening memory chip supply resilience** through multi-year agreements
- Driving **PCS backlog conversion** and creating momentum for a sustained recovery

3Q 2026 Consolidated performance summary

Revenues

\$5.5B

6.2% YoY
Organic growth^{*(1)}

Organic orders growth**

4.0% YoY

Book-to-Bill**
1.03x

Backlog**
\$23.7B

Adjusted EBIT* and Adjusted EBIT margin*

\$913M

16.6% Margin
180 bps YoY

Adjusted EPS*

\$1.34

25.1% YoY


Free cash flow*

\$793M

\$310M YoY

Heartbeat supports growth and margin expansion

3Q Adjusted EBIT margin* performance YoY



Building blocks for expansion

Commercial execution

- Strategic pricing opportunities
- Standard product launch playbook
- New products at higher gross margins

Operational simplification


- Platforming and variable cost productivity
- Organizational and structural cost optimization
- Internal process simplification

3Q 2026 Segment results

	Advanced Imaging Solutions	Pharmaceutical Diagnostics	Patient Care Solutions
Revenues YoY change ^{(1)*}	\$3,873M 4.5%	\$846M 13.8%	\$793M 8.8%
Segment EBIT YoY change	\$593M 15.8%	\$253M 14.9%	\$68M 148.8%
Segment EBIT margin YoY change	15.3% 130 bps	29.9% 50 bps	8.6% 480 bps
Highlights	- Organic revenue growth* driven by strength in CT, CardioVascular and Interventional Solutions, and Surgical Innovations - EBIT performance benefited from volume growth, tariff favorability and price, partially offset by inflation Broad-based demand in high growth areas such as cardiology and oncology	- Robust Organic revenue growth* driven by contrast media, radiopharmaceutical portfolio, and price - EBIT margin expansion YoY driven by strong volume and price, partially offset by planned investments in launches and pipeline - Announced planned acquisition of SOFIE Biosciences⁽²⁾ to broaden footprint in radiopharmaceutical industry	- Organic revenue growth* driven by improved product fulfillment in Monitoring and Maternal Infant Care - EBIT margin expansion driven by higher volume and cost productivity - Second-half stabilization on track, supported by customer demand and operational execution

Cash performance and capital deployment priorities

3Q 2026 Free cash flow*



Capital deployment highlights

- Delivered \$793M in Free cash flow* in the quarter
- YoY Free cash flow* increase supported by lower net tariff impact, operational profitability, and collections timing
- Continue to deliver returns to shareholders; increased cash dividend 14%

* Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.

2026 Outlook

	2025A	Previous 2026E	Updated 2026E
Organic Revenue Growth ^{*(1)}	3.5%	3.0% - 4.0%	~4.0%
Adjusted EBIT Margin*	15.3%	15.4% - 15.7% 10 – 40 bps	15.5% - 15.7% 20 – 40 bps
Adjusted ETR*	20.2%	20.0% - 21.0%	Reaffirmed
Adjusted EPS*	\$4.59	\$4.80 - \$5.00 4.6% - 9.0%	\$4.95 - \$5.05 7.9% - 10.1%
Free Cash Flow*	\$1.5B	~\$1.6B	\$1.6B+

* Non-GAAP financial measure. See appendix for reconciliation of historical GAAP to non-GAAP financial measures and for more information on our Outlook.

(1) Figures represent comparison to previous year on an Organic* basis.


PDx: a consistent growth driver and precision care enabler

D3: Smart devices and drugs, focused on disease states and supported by digital tools like AI and software

Portfolio momentum

Rising disease incidence drives demand

Contrast media growth supported by resilient supply; radiopharmaceutical growth in neurology, oncology and cardiology



■ Contrast media

■ Radiopharma

Precision care ecosystem

Right treatment, right patient, right time


Contrast media & radiopharmaceutical agents complement imaging devices, AI and software across diseases



Innovation pipeline

Investing in the next decade

Led by mangaciclano⁽¹⁾ and FAPI; future platforms and lifecycle innovation in development



Strategic expansion

SOFIE Biosciences⁽²⁾

Upon close, would add U.S. “final mile” PET supply and manufacturing and U.S. rights to Phase 3 FAPI-74



Recurring revenue and innovation across the portfolio drive long-term value

Summary

- Strong top-line growth and margin improvement across the portfolio
- Leveraged Heartbeat to drive commercial execution and operational performance
- Advanced our new wave of innovation by achieving key regulatory milestones
- Year-to-date momentum gives us confidence in our growth outlook

Note: Not all products available in all regions.



Intermountain Health in Utah was an early adopter of **GE HealthCare's SIGNA™ Sprint Elite MR system** to help enable improved diagnosis for cardiac and cancer patients



GE HealthCare

Q&A

Upcoming events

Investor Forum at RSNA	December 1, 2026
------------------------	------------------

JP Morgan Healthcare Conference	January 2027
---------------------------------	--------------

Appendix

Organic Revenue*

(\$ in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	% change	2026	2025	% change
Total revenues	\$ 5,513	\$ 5,143	7.2 %	\$ 15,939	\$ 14,927	6.8 %
<i>Less: Acquisitions⁽¹⁾</i>	68	—		190	1	
<i>Less: Dispositions⁽²⁾</i>	—	—		—	—	
<i>Less: Foreign currency exchange</i>	(16)	—		189	—	
Organic revenue*	\$ 5,462	\$ 5,143	6.2 %	\$ 15,560	\$ 14,926	4.2 %

(1) Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.

(2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

*Non-GAAP financial measure.

Segment Organic Revenue*

(\$ in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	% change	2026	2025	% change
AIS revenues	\$ 3,873	\$ 3,649	6.1 %	\$ 11,284	\$ 10,522	7.2 %
<i>Less: Acquisitions⁽¹⁾</i>	68	—		140	—	
<i>Less: Dispositions⁽²⁾</i>	—	—		—	—	
<i>Less: Foreign currency exchange</i>	(8)	—		148	—	
AIS Organic revenue*	\$ 3,814	\$ 3,649	4.5 %	\$ 10,996	\$ 10,522	4.5 %
PDx revenues	\$ 846	\$ 749	13.0 %	\$ 2,458	\$ 2,110	16.5 %
<i>Less: Acquisitions⁽¹⁾</i>	—	—		50	1	
<i>Less: Dispositions⁽²⁾</i>	—	—		—	—	
<i>Less: Foreign currency exchange</i>	(6)	—		29	—	
PDx Organic revenue*	\$ 852	\$ 749	13.8 %	\$ 2,379	\$ 2,109	12.8 %
PCS revenues	\$ 793	\$ 731	8.5 %	\$ 2,171	\$ 2,262	(4.0)%
<i>Less: Acquisitions⁽¹⁾</i>	—	—		—	—	
<i>Less: Dispositions⁽²⁾</i>	—	—		—	—	
<i>Less: Foreign currency exchange</i>	(2)	—		12	—	
PCS Organic revenue*	\$ 795	\$ 731	8.8 %	\$ 2,159	\$ 2,262	(4.5)%

(1) Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.

(2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

*Non-GAAP financial measure.

Adjusted EBIT*

(\$ in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	% change	2026	2025	% change
Net income attributable to GE HealthCare	\$ 615	\$ 446	37.9 %	\$ 1,564	\$ 1,495	4.6 %
<i>Add: Interest and other financial charges – net</i>	122	111		332	335	
<i>Add: Non-operating benefit (income) costs</i>	(50)	(75)		(146)	(222)	
<i>Less: Benefit (provision) for income taxes</i>	(129)	(179)		(342)	(395)	
<i>Less: Net (income) loss attributable to noncontrolling interests</i>	(9)	(18)		(44)	(57)	
EBIT*	824	679	21.3 %	2,136	2,060	3.7 %
<i>Add: Restructuring costs⁽¹⁾</i>	17	31		92	71	
<i>Add: Acquisition and disposition-related charges (benefits)⁽²⁾</i>	11	9		57	24	
<i>Add: Spin-Off and separation costs and other adjustments⁽³⁾</i>	4	6		2	35	
<i>Add: (Gain) loss on business and asset dispositions⁽⁴⁾</i>	(2)	—		(2)	(5)	
<i>Add: Amortization of acquisition-related intangible assets</i>	61	41		169	116	
<i>Add: Investment revaluation (gain) loss⁽⁵⁾</i>	6	(4)		14	(96)	
<i>Less: Tariff refunds⁽⁶⁾</i>	9	—		115	—	
Adjusted EBIT*	\$ 913	\$ 761	19.9 %	\$ 2,353	\$ 2,205	6.7 %
Net income margin	11.1 %	8.7 %	250 bps	9.8 %	10.0 %	(20) bps
Adjusted EBIT margin*	16.6 %	14.8 %	180 bps	14.8 %	14.8 %	— bps

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments and for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025.

* Non-GAAP financial measure.

Adjusted Net Income*

(\$ in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	% change	2026	2025	% change
Net income attributable to GE HealthCare	\$ 615	\$ 446	37.9 %	\$ 1,564	\$ 1,495	4.6 %
Add: Non-operating benefit (income) costs	(50)	(75)		(146)	(222)	
Add: Restructuring costs ⁽¹⁾	17	31		92	71	
Add: Acquisition and disposition-related charges (benefits) ⁽²⁾	11	9		57	24	
Add: Spin-Off and separation costs and other adjustments ⁽³⁾	4	6		2	40	
Add: (Gain) loss on business and asset dispositions ⁽⁴⁾	(2)	—		(2)	(5)	
Add: Amortization of acquisition-related intangible assets	61	41		169	116	
Add: Investment revaluation (gain) loss ⁽⁵⁾	6	(4)		14	(96)	
Less: Tariff refunds ⁽⁶⁾	9	—		115	—	
Add: Tax effect of reconciling items ⁽⁷⁾	(7)	(2)		(16)	(3)	
Add: Spin-Off and other tax adjustments ⁽⁸⁾	(37)	39		(45)	22	
Adjusted net income*	\$ 608	\$ 490	24.0 %	\$ 1,575	\$ 1,441	9.3 %

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. For the nine months ended September 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments and for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is \$7 million and \$88 million for the three and nine months ended September 30, 2026, respectively.

(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.

* Non-GAAP financial measure.

Adjusted Earnings Per Share*

(In dollars, except shares outstanding presented in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	\$ change	2026	2025	\$ change
Diluted earnings per share	\$ 1.36	\$ 0.98	\$ 0.38	\$ 3.44	\$ 3.26	\$ 0.18
Add: Non-operating benefit (income) costs	(0.11)	(0.16)		(0.32)	(0.49)	
Add: Restructuring costs ⁽¹⁾	0.04	0.07		0.20	0.16	
Add: Acquisition and disposition-related charges (benefits) ⁽²⁾	0.03	0.02		0.13	0.05	
Add: Spin-Off and separation costs and other adjustments ⁽³⁾	0.01	0.01		0.00	0.09	
Add: (Gain) loss on business and asset dispositions ⁽⁴⁾	(0.00)	—		(0.00)	(0.01)	
Add: Amortization of acquisition-related intangible assets	0.13	0.09		0.37	0.25	
Add: Investment revaluation (gain) loss ⁽⁵⁾	0.01	(0.01)		0.03	(0.21)	
Less: Tariff refunds ⁽⁶⁾	0.02	—		0.25	—	
Add: Tax effect of reconciling items ⁽⁷⁾	(0.02)	(0.00)		(0.03)	(0.01)	
Add: Spin-Off and other tax adjustments ⁽⁸⁾	(0.08)	0.09		(0.10)	0.05	
Adjusted earnings per share*	\$ 1.34	\$ 1.07	\$ 0.27	\$ 3.46	\$ 3.15	\$ 0.32
Diluted weighted-average shares outstanding	453	457		455	458	

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. For the nine months ended September 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments and for the nine months ended September 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is \$0.02 and \$0.19 for the three and nine months ended September 30, 2026, respectively.

(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.

* Non-GAAP financial measure.

Adjusted Tax Expense* and Adjusted ETR*

(\$ in millions)

Unaudited	For the three months ended September 30		For the nine months ended September 30	
	2026	2025	2026	2025
Benefit (provision) for income taxes	\$ (129)	\$ (179)	\$ (342)	\$ (395)
<i>Add: Tax effect of reconciling items⁽¹⁾</i>	(7)	(2)	(16)	(3)
<i>Add: Spin-Off and other tax adjustments⁽²⁾</i>	(37)	39	(45)	22
Adjusted tax expense*	\$ (174)	\$ (142)	\$ (402)	\$ (377)
Effective tax rate	17.1%	27.8%	17.5%	20.3%
Adjusted effective tax rate*	22.0%	21.8%	19.9%	20.2%

(1) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(2) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE. Additionally, includes the impact of a foreign tax audit settlement for the three and nine months ended September 30, 2026; impacts from tax law changes for the three and nine months ended September 30, 2025; and tax impacts of the NMP acquisition for the nine months ended September 30, 2025.

* Non-GAAP financial measure.

Free Cash Flow*

(\$ in millions)

Unaudited	For the three months ended September 30			For the nine months ended September 30		
	2026	2025	% change	2026	2025	% change
Cash from (used for) operating activities	\$ 907	\$ 593	52.9 %	\$ 1,365	\$ 937	45.6 %
<i>Add: Additions to PP&E and internal-use software</i>	(114)	(110)		(392)	(348)	
<i>Add: Dispositions of PP&E</i>	—	—		—	—	
Free cash flow*	\$ 793	\$ 483	64.2 %	\$ 973	\$ 589	65.2 %

*Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 3Q 2026

(\$ in millions)

Unaudited	GAAP Reported	Restructuring costs(1)	Acquisition and disposition- related charges (benefits)(2)	Spin-Off and separation costs(3)	(Gain) loss on business and asset dispositions(4)	Amortization of acquisition- related intangible assets	Investment revaluation (gain) loss(5)	Tariff Refunds(6)	Non- Operating benefit (income) costs	Tax effect of reconciling items(7)	Spin-Off and other tax adjustments (8)	Non-GAAP Results*
Total revenues	\$ 5,513											\$ 5,513
<i>Cost of revenues</i>	3,289	(4)	—	—		(49)		9				3,245
Gross profit	2,224	4	—	—	—	49	—	(9)	—	—	—	2,268
<i>Selling, general, and administrative</i>	1,100	(13)	(10)	—		(9)						1,068
<i>Research and development</i>	320		(1)	—		(4)						315
Operating income	805	17	11	—	—	61	—	(9)	—	—	—	885
<i>Other (income) expense - net</i>	(19)	—	—	(4)	2		(6)					(28)
<i>Interest and other financial charges - net</i>	122											122
<i>Non-operating benefit (income) costs</i>	(50)								50			—
<i>Benefit (provision) for income taxes</i>	(129)									(7)	(37)	(174)
<i>Net (income) loss attributable to NCI</i>	(9)											(9)
Net income attributable to GE HealthCare	\$ 615	\$ 17	\$ 11	\$ 4	\$ (2)	\$ 61	\$ 6	\$ (9)	\$ (50)	\$ (7)	\$ (37)	\$ 608
Gross profit margin	40.3 %											41.1 %

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is \$7 million for the three months ended September 30, 2026.

(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE, and the impact of a foreign tax audit settlement.

* Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 3Q 2025

(\$ in millions)

Unaudited	GAAP Reported	Restructuring costs ⁽¹⁾	Acquisition and disposition- related charges (benefits) ⁽²⁾	Spin-Off and separation costs and other adjustments ⁽³⁾	(Gain) loss on business and asset dispositions ⁽⁴⁾	Amortization of acquisition- related intangible assets	Investment revaluation (gain) loss ⁽⁵⁾	Non- Operating benefit (income) costs	Tax effect of reconciling items ⁽⁶⁾	Spin-Off and other tax adjustments ⁽⁷⁾	Non-GAAP Results*
Total revenues	\$ 5,143										\$ 5,143
<i>Cost of revenues</i>	3,154	(10)	—	(1)		(34)					3,109
Gross profit	1,990	10	—	1	—	34	—	—	—	—	2,035
<i>Selling, general, and administrative</i>	1,045	(21)	(8)	(4)		(6)					1,005
<i>Research and development</i>	292		—	(1)							291
Operating income	653	31	9	6	—	41	—	—	—	—	739
<i>Other (income) expense - net</i>	(26)	—	—	—	—		4				(23)
<i>Interest and other financial charges - net</i>	111										111
<i>Non-operating benefit (income) costs</i>	(75)							75			—
<i>Benefit (provision) for income taxes</i>	(179)								(2)	39	(142)
<i>Net (income) loss attributable to NCI</i>	(18)										(18)
Net income attributable to GE HealthCare	\$ 446	\$ 31	\$ 9	\$ 6	\$ —	\$ 41	\$ (4)	\$ (75)	\$ (2)	\$ 39	\$ 490
Gross profit margin	38.7 %										39.6 %

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments.

(6) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(7) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE, and impacts from tax law changes.

* Non-GAAP financial measure.

Acronyms

AI	Artificial Intelligence
AIS	Advanced Imaging Solutions
bps	Basis points
CE	Conformité Européenne
CT	Computed Tomography
EBIT	Earnings Before Interest and Taxes
EPS	Earnings Per Share
ETR	Effective Tax Rate
EU	European Union
FDA	Food and Drug Administration
FX	Foreign Exchange
MI	Molecular Imaging
NMP	Nihon Medi-Physics
NPIs	New Product Introductions
PCS	Patient Care Solutions
PDx	Pharmaceutical Diagnostics
PP&E	Property, Plant, and Equipment
SaaS	Software as a Service
YoY	Year-over-Year

Definitions

Backlog	The estimated revenue expected from customer contracts that are partially or fully unperformed including amounts deferred in contract liabilities; contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty; and lease contracts
Book-to-Bill	Total orders divided by total revenues within a given financial period (e.g., quarter or FY)
Capital Expenditures	Capital Expenditures represent Additions to property, plant and equipment and internal-use software included in the Condensed Consolidated Statements of Cash Flows
Free cash flow conversion*	Free cash flow* divided by Adjusted net income*
Orders	Contractual commitments with customers to provide specified goods or services for an agreed upon price
Organic orders growth	Rate of change period-over-period of contractual commitments with customers to provide specified goods or services for an agreed upon price, and excluding the effects of: (1) recent acquisitions and dispositions with less than a full year of comparable orders; and (2) foreign currency exchange rate fluctuations in order to present orders on a constant currency basis
Products	Sales of medical equipment, contrast agents (PDx), software licenses (excludes hosting/SaaS), Options and Upgrades
Services	Maintenance and repair services for equipment, training, parts, software hosting (Software as a Service (SaaS))



Non-GAAP Financial Measures

The non-GAAP financial measures presented in this presentation are supplemental measures of GE HealthCare's performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company's U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare's underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.

The Company reports **Organic revenue and Organic revenue growth rate** to provide management and investors with additional understanding and visibility into the underlying revenue trends of its established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations.

The Company reports **Adjusted gross profit, Adjusted gross profit margin, EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share** to provide management and investors with an additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations elsewhere in this presentation, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted gross profit margin and Adjusted EBIT margin are calculated by taking Adjusted gross profit or Adjusted EBIT, divided by Total revenues for the same period.

The Company reports **Adjusted tax expense and Adjusted ETR** to provide management and investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above.

The Company reports **Free cash flow and Free cash flow conversion** to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company's flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of PP&E and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income.

Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided elsewhere in this presentation, and no single financial measure should be relied on to evaluate our business.

Non-GAAP Financial Measures in Outlook

GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in U.S. GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective U.S. GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare's results in accordance with U.S. GAAP.